Presentation is loading. Please wait.

Presentation is loading. Please wait.

ESKM treatment does not affect leukocyte or HSC counts in HLA-A

Published byAbel Harper Modified over 5 years ago

Similar presentations

Presentation on theme: "ESKM treatment does not affect leukocyte or HSC counts in HLA-A"— Presentation transcript:

1 ESKM treatment does not affect leukocyte or HSC counts in HLA-A
ESKM treatment does not affect leukocyte or HSC counts in HLA-A*02:01+ transgenic mice. ESKM treatment does not affect leukocyte or HSC counts in HLA-A*02:01+ transgenic mice. Animals (n = 5 per group) were treated with 100 μg ESKM or hIgG1 isotype control on days 0 and 4; blood and bone marrow were harvested on day 5. Data points are averages of each group, and error bars represent SEM. A, total white blood cell (WBC) and WBC subset cell counts. B, absolute number and frequency of lineage− SCA1+ KIT+ (LSK) cells. C, absolute number and frequency of long-term HSCs (Slamf1+ CD34− LSK cells). Nicholas Veomett et al. Clin Cancer Res 2014;20: ©2014 by American Association for Cancer Research

Download ppt "ESKM treatment does not affect leukocyte or HSC counts in HLA-A"

Similar presentations

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.

Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.
TLR5 signaling in murine bone marrow induces hematopoietic progenitor cell proliferation and aids survival from radiation by Benyue Zhang, Damilola Oyewole-Said,

TLR5 signaling in murine bone marrow induces hematopoietic progenitor cell proliferation and aids survival from radiation by Benyue Zhang, Damilola Oyewole-Said,
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Volume 3, Issue 4, Pages (October 2008)

Volume 3, Issue 4, Pages (October 2008)
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
Viral load and CD4+ T cells in CD8+ T cell–depleted YU-2–infected MISTRG mice. Viral load and CD4+ T cells in CD8+ T cell–depleted YU-2–infected MISTRG.

Viral load and CD4+ T cells in CD8+ T cell–depleted YU-2–infected MISTRG mice. Viral load and CD4+ T cells in CD8+ T cell–depleted YU-2–infected MISTRG.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.
Fig. 4. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist, on anemic rodents. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist,

Fig. 4. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist, on anemic rodents. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist,
ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Mark J. Kiel, Melih Acar, Glenn L. Radice, Sean J. Morrison 

Mark J. Kiel, Melih Acar, Glenn L. Radice, Sean J. Morrison 
P53 inhibition impairs expansion of HSCs with VPA by increasing ROS levels. p53 inhibition impairs expansion of HSCs with VPA by increasing ROS levels.

P53 inhibition impairs expansion of HSCs with VPA by increasing ROS levels. p53 inhibition impairs expansion of HSCs with VPA by increasing ROS levels.
Comparison of absolute counts for a, b) white blood cells (WBC), c, d) neutrophils, e, f) monocytes, and g, h) eosinophils for 100 patients with lymphangioleiomyomatosis.

Comparison of absolute counts for a, b) white blood cells (WBC), c, d) neutrophils, e, f) monocytes, and g, h) eosinophils for 100 patients with lymphangioleiomyomatosis.
IBD development correlates with peripheral T cell activation in DNR mice. IBD development correlates with peripheral T cell activation in DNR mice. (A)

IBD development correlates with peripheral T cell activation in DNR mice. IBD development correlates with peripheral T cell activation in DNR mice. (A)
CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.
Figure 4. p38α mitogen-activated protein kinase (MAPK) blockade reduces interstitial volume in obstructed kidneys but does not reduce the number of infiltrating.

Figure 4. p38α mitogen-activated protein kinase (MAPK) blockade reduces interstitial volume in obstructed kidneys but does not reduce the number of infiltrating.
by Yue Wei, Hong Zheng, Naran Bao, Shan Jiang, Carlos E

by Yue Wei, Hong Zheng, Naran Bao, Shan Jiang, Carlos E
Schematic depiction of CTC processing methods.

Schematic depiction of CTC processing methods.

Similar presentations

Ads by Google